Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy
Journal for ImmunoTherapy of Cancer · 2024-07 · 12 (7) · e008953
DOI: 10.1136/jitc-2024-008953 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 18.07.2024. Verfasst von Yonglin Hua und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Quinolines, Machine Learning. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: KunLun Outstanding Innovation and Entrepreneurship Talent Program, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Lenvatinib plus PD-1 inhibitors and interventional (LPI) therapy have demonstrated promising treatment effects in unresectable hepatocellular carcinoma (HCC). However, biomarkers for predicting the response to LPI therapy remain to be further explored. We aimed to develop a radiomics model to noninvasively predict the efficacy of LPI therapy.
Methods
Clinical data of patients with HCC receiving LPI therapy were collected in our institution. The clinical model was built with clinical information. Nine machine learning classifiers were tested and the multilayer perceptron classifier with optimal performance was used as the radiomics model. The clinical-radiomics model was constructed by integrating clinical and radiomics scores through logistic regression analysis.
Results
151 patients were enrolled in this study (2:1 randomization, 101 and 50 in the training and validation cohorts), of which three achieved complete response, 69 showed partial response, 46 showed stable disease, and 33 showed progressive disease. The objective response rate, disease control rate, and conversion resection rates were 47.7, 78.1 and 23.2%. 14 features were selected from the initially extracted 1223 for radiomics model construction. The area under the curves of the radiomics model (0.900 for training and 0.893 for validation) were comparable to that of the clinical-radiomics model (0.912 for training and 0.892 for validation), and both were superior to the clinical model (0.669 for training and 0.585 for validation). Meanwhile, the radiomics model can categorize participants into high-risk and low-risk groups for progression-free survival (PFS) and overall survival (OS) in the training (HR 1.913, 95% CI 1.121 to 3.265, p=0.016 for PFS; HR 4.252, 95% CI 2.051 to 8.816, p=0.001 for OS) and validation sets (HR 2.347, 95% CI 1.095 to 5.031, p=0.012 for PFS; HR 2.592, 95% CI 1.050 to 6.394, p=0.019 for OS).
Conclusion
The promising machine learning radiomics model was developed and validated to predict the efficacy of LPI therapy for patients with HCC and perform risk stratification, with comparable performance to clinical-radiomics model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China.
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.
- Breast Disease Center, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
- Laboratory of General Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
- Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
ORCID-Profile: Changzhen Shang
Förderung
- KunLun Outstanding Innovation and Entrepreneurship Talent Program
- National Natural Science Foundation of China
Zitieren
APA
Hua, Y., Sun, Z., Xiao, Y., Li, H., Ma, X., Luo, X., Tan, W., Xie, Z., Zhang, Z., Tang, C., Zhuang, H., Xu, W., Zhu, H., Chen, Y., & Shang, C. (2024). Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy. Journal for ImmunoTherapy of Cancer, 12(7), e008953. https://doi.org/10.1136/jitc-2024-008953
Vancouver
Hua Y, Sun Z, Xiao Y, Li H, Ma X, Luo X, et al. Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy. Journal for ImmunoTherapy of Cancer. 2024;12(7):e008953. doi:10.1136/jitc-2024-008953
BibTeX
@article{Hua2024,
author = {Hua, Yonglin and Sun, Zhixian and Xiao, Yuxin and Li, Huilong and Ma, Xiaowu and Luo, Xuan and Tan, Wenliang and Xie, Zhiqin and Zhang, Ziyu and Tang, Chenwei and Zhuang, Hongkai and Xu, Weikai and Zhu, Haihong and Chen, Yajin and Shang, Changzhen},
title = {Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {7},
pages = {e008953},
doi = {10.1136/jitc-2024-008953}
}
EUVIMED